Ameriprise
XENE icon

Ameriprise’s Xenon Pharmaceuticals XENE Stock Holding History

Ameriprise’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.2M Buy
318,548
+239,643
+304% +$13.3M ﹤0.01% 1562
2026
Q1 		$4.59M Sell
78,905
-30,639
-28% -$1.41M ﹤0.01% 2487
2025
Q4 		$4.91M Buy
109,544
+11,977
+12% +$503K ﹤0.01% 2448
2025
Q3 		$3.92M Sell
97,567
-24,459
-20% -$861K ﹤0.01% 2606
2025
Q2 		$3.82M Buy
122,026
+18,402
+18% +$600K ﹤0.01% 2556
2025
Q1 		$3.48M Buy
103,624
+11,274
+12% +$428K ﹤0.01% 2568
2024
Q4 		$3.62M Buy
92,350
+25,967
+39% +$1.07M ﹤0.01% 2585
2024
Q3 		$2.61M Buy
+66,383
New +$2.68M ﹤0.01% 2770
2023
Q1 		– Sell
-22,626
Closed -$891K – 4041
2022
Q4 		$891K Sell
22,626
-18,518
-45% -$674K ﹤0.01% 3191
2022
Q3 		$1.49M Sell
41,144
-10,032
-20% -$361K ﹤0.01% 2921
2022
Q2 		$1.56M Sell
51,176
-6,756
-12% -$204K ﹤0.01% 2918
2022
Q1 		$1.77M Sell
57,932
-389
-0.7% -$11.6K ﹤0.01% 2962
2021
Q4 		$1.82M Buy
58,321
+43,621
+297% +$1.3M ﹤0.01% 2986
2021
Q3 		$225K Buy
+14,700
New +$255K ﹤0.01% 3675

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Ameriprise's XENE Position: Q2 2026 in Review

Ameriprise increased its Xenon Pharmaceuticals (XENE) stake by 304% in Q2 2026, buying an estimated $13.3M and bringing the position to 318,548 shares worth $19.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

Ameriprise first reported a position in XENE in Q3 2021 and has held it in 14 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Ameriprise held 318,548 shares of Xenon Pharmaceuticals worth $19.2M as of Q2 2026.
  • Ameriprise bought 239,643 Xenon Pharmaceuticals shares in Q2 2026, an estimated $13.3M.
  • Xenon Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1562 holding.
  • Ameriprise first reported a position in Xenon Pharmaceuticals in Q3 2021 and has held it in 14 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.